Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giampaolo Merlini

Showing results (1-10 of 458) with videos related to

Pageof 46
Sort By:
The New England Journal of Medicine|January 3, 2025
Vutrisiran for ATTR Amyloidosis with CardiomyopathyGiampaolo Merlini
Blood|May 12, 2012
CyBorD: stellar response rates in AL amyloidosisGiampaolo Merlini
Hematology. American Society of Hematology. Education Program|December 10, 2017
AL amyloidosis: from molecular mechanisms to targeted therapiesGiampaolo Merlini
The New England Journal of Medicine|October 27, 2023
A Step Forward in Solving AmyloidosisGiampaolo Merlini
Clinical Chemistry and Laboratory Medicine|September 5, 2009
Serum-free light chain analysis: works in progressGiampaolo Merlini
Hematology/Oncology Clinics of North America|October 25, 2020
IntroductionGiampaolo Merlini
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 15, 2011
Reducing the amyloid burden through immunotherapy: a major therapeutic advanceGiampaolo Merlini
Blood|January 18, 2014
Determining the significance of MGUSGiampaolo Merlini
Hematology/Oncology Clinics of North America|October 25, 2020
Future PerspectivesAngela Dispenzieri, Giampaolo Merlini
Expert Opinion on Investigational Drugs|July 9, 2014
An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosisLaura Obici, Giampaolo Merlini
Pageof 46

Showing results (1-10 of 458) with videos related to

Sort By:
Pageof 46
The New England Journal of Medicine|January 3, 2025
Vutrisiran for ATTR Amyloidosis with CardiomyopathyGiampaolo Merlini
Blood|May 12, 2012
CyBorD: stellar response rates in AL amyloidosisGiampaolo Merlini
Hematology. American Society of Hematology. Education Program|December 10, 2017
AL amyloidosis: from molecular mechanisms to targeted therapiesGiampaolo Merlini
The New England Journal of Medicine|October 27, 2023
A Step Forward in Solving AmyloidosisGiampaolo Merlini
Clinical Chemistry and Laboratory Medicine|September 5, 2009
Serum-free light chain analysis: works in progressGiampaolo Merlini
Hematology/Oncology Clinics of North America|October 25, 2020
IntroductionGiampaolo Merlini
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 15, 2011
Reducing the amyloid burden through immunotherapy: a major therapeutic advanceGiampaolo Merlini
Blood|January 18, 2014
Determining the significance of MGUSGiampaolo Merlini
Hematology/Oncology Clinics of North America|October 25, 2020
Future PerspectivesAngela Dispenzieri, Giampaolo Merlini
Expert Opinion on Investigational Drugs|July 9, 2014
An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosisLaura Obici, Giampaolo Merlini
Pageof 46